Prestige Consumer Healthcare (PBH) Income from Continuing Operations (2010 - 2025)
Prestige Consumer Healthcare (PBH) recorded quarterly Income from Continuing Operations of 46696000.0 in Q4 2025, up 10.63% quarter-over-quarter from 42211000.0 in Q3 2025, and down 23.49% on a YoY basis from 61032000.0 in Q4 2024.
Prestige Consumer Healthcare (PBH) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 46696000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 23.49% year-over-year to 46696000.0; the TTM figure through Dec 2025 stood at 186501000.0 (down 12.82% YoY), while the FY2025 annual figure was 214605000.0, up 2.52% from the prior year.
- Income from Continuing Operations was 46696000.0 for Q4 2025 at Prestige Consumer Healthcare, up from 42211000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 61032000.0 in Q4 2024 to a low of 240552000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 35945300.0 across 5 years, with a median of 50619000.0 in 2021.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 561.84% in 2023, then soared 120.56% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 50215000.0 in 2021, then increased by 3.46% to 51951000.0 in 2022, then grew by 2.11% to 53046000.0 in 2023, then grew by 15.05% to 61032000.0 in 2024, then dropped by 23.49% to 46696000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 46696000.0 (Q4 2025), 42211000.0 (Q3 2025), and 47466000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Prestige Consumer Healthcare | 2.33 Bn | 2.26 Bn | 157.37 Mn | 46.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.70 Mn |
| Sep 30, 2025 | 42.21 Mn |
| Jun 30, 2025 | 47.47 Mn |
| Mar 31, 2025 | 50.13 Mn |
| Dec 31, 2024 | 61.03 Mn |
| Sep 30, 2024 | 54.38 Mn |
| Jun 30, 2024 | 49.07 Mn |
| Mar 31, 2024 | 49.46 Mn |
| Dec 31, 2023 | 53.05 Mn |
| Sep 30, 2023 | 53.56 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | -240.55 Mn |
| Dec 31, 2022 | 51.95 Mn |
| Sep 30, 2022 | 51.02 Mn |
| Jun 30, 2022 | 55.27 Mn |
| Mar 31, 2022 | 52.09 Mn |
| Dec 31, 2021 | 50.22 Mn |
| Sep 30, 2021 | 45.33 Mn |
| Jun 30, 2021 | 57.76 Mn |
| Mar 31, 2021 | 35.51 Mn |